Ines Labugger1, Jan Heyckendorf2,3,4, Stefan Dees1, Emilia Häussinger5, Christian Herzmann6, Thomas A Kohl7, Elvira Richter8,9, Eric Rivera-Milla1, Christoph Lange5,10,11,12,13. 1. Alere Technologies GmbH, Jena, Germany. 2. Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. jheyckendorf@fz-borstel.de. 3. German Center for Infection Research (DZIF), partner site Borstel, Research Center Borstel, Borstel, Germany. jheyckendorf@fz-borstel.de. 4. International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany. jheyckendorf@fz-borstel.de. 5. Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. 6. Center for Clinical Studies, Research Center Borstel, Borstel, Germany. 7. Division of Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany. 8. Division of Mycobacteriology, Research Center Borstel, Borstel, Germany. 9. Laboratory Dr. Limbach, Heidelberg, Germany. 10. German Center for Infection Research (DZIF), partner site Borstel, Research Center Borstel, Borstel, Germany. 11. International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany. 12. Department of Medicine, Karolinska Institute, Stockholm, Sweden. 13. Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
Abstract
PURPOSE: Molecular diagnostics of patients with MTB tuberculosis from urine samples. METHODS: We developed a new molecular assay based on the detection of M. tuberculosis-specific transrenal DNA (trDNA) and tested it for the diagnosis of active tuberculosis at the initiation of anti-tuberculosis therapy and during treatment follow-up. RESULTS: The overall sensitivity of trDNA was 96 and 100% when smear-microscopy and trDNA was combined. In a subset of TB treatment naïve patients (n = 11) sensitivity and specificity of trDNA was 64 and 100%, respectively. For this subset of patients the sensitivity was 91% when smear-microscopy and trDNA diagnosis were combined. After treatment initiation, trDNA showed a significant reduction in concentration over time reaching undetectable trDNA values at week 12 in 9 of 11 accessible patients (82%). Kinetics in treatment-naïve patients showed low base-line trDNA levels, which increased to maximal trDNA levels within one week indicating bactericidal activity of anti-tuberculosis drugs after the initiation of effective therapy. Maximal trDNA levels correlated positively with a radiological score, suggesting that the process of DNA excretion may reflect the extent of pulmonary disease. Matched samples showed an inverse correlation between the time to positivity of solid culture with maximum trDNA levels as well as the expected positive correlation between smear grade and maximum trDNA values. CONCLUSION: The detection of M. tuberculosis trDNA from urine specimen is a promising method for the diagnosis tuberculosis. The assay may be a candidate diagnostic tool for patients with paucibacillary and extrapulmonary disease, as method to assess treatment responses and could be helpful to diagnose tuberculosis in children.
PURPOSE: Molecular diagnostics of patients with MTB tuberculosis from urine samples. METHODS: We developed a new molecular assay based on the detection of M. tuberculosis-specific transrenal DNA (trDNA) and tested it for the diagnosis of active tuberculosis at the initiation of anti-tuberculosis therapy and during treatment follow-up. RESULTS: The overall sensitivity of trDNA was 96 and 100% when smear-microscopy and trDNA was combined. In a subset of TB treatment naïve patients (n = 11) sensitivity and specificity of trDNA was 64 and 100%, respectively. For this subset of patients the sensitivity was 91% when smear-microscopy and trDNA diagnosis were combined. After treatment initiation, trDNA showed a significant reduction in concentration over time reaching undetectable trDNA values at week 12 in 9 of 11 accessible patients (82%). Kinetics in treatment-naïve patients showed low base-line trDNA levels, which increased to maximal trDNA levels within one week indicating bactericidal activity of anti-tuberculosis drugs after the initiation of effective therapy. Maximal trDNA levels correlated positively with a radiological score, suggesting that the process of DNA excretion may reflect the extent of pulmonary disease. Matched samples showed an inverse correlation between the time to positivity of solid culture with maximum trDNA levels as well as the expected positive correlation between smear grade and maximum trDNA values. CONCLUSION: The detection of M. tuberculosis trDNA from urine specimen is a promising method for the diagnosis tuberculosis. The assay may be a candidate diagnostic tool for patients with paucibacillary and extrapulmonary disease, as method to assess treatment responses and could be helpful to diagnose tuberculosis in children.
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: A Cannas; D Goletti; E Girardi; T Chiacchio; L Calvo; G Cuzzi; M Piacentini; H Melkonyan; S R Umansky; F N Lauria; G Ippolito; L D Tomei Journal: Int J Tuberc Lung Dis Date: 2008-02 Impact factor: 2.373
Authors: N R Pollock; A T MacIntyre; T A Blauwkamp; L Blair; C Ho; R Calderon; M F Franke Journal: Int J Tuberc Lung Dis Date: 2021-05-01 Impact factor: 2.373
Authors: Annelies W Mesman; Roger I Calderon; Nira R Pollock; Martín Soto; Milagros Mendoza; Julia Coit; Zibiao Zhang; Juan Aliaga; Leonid Lecca; Rebecca C Holmberg; Molly F Franke Journal: Sci Rep Date: 2020-12-17 Impact factor: 4.379
Authors: Zhen Huang; Sylvia M LaCourse; Alexander W Kay; Joshua Stern; Jaclyn N Escudero; Brady M Youngquist; Wenshu Zheng; Debrah Vambe; Muyalo Dlamini; Godwin Mtetwa; Lisa M Cranmer; Irene Njuguna; Dalton C Wamalwa; Elizabeth Maleche-Obimbo; Donald G Catanzaro; Christopher J Lyon; Grace John-Stewart; Andrew DiNardo; Anna M Mandalakas; Bo Ning; Tony Y Hu Journal: Lancet Microbe Date: 2022-05-31
Authors: Christoph Lange; Rob Aarnoutse; Dumitru Chesov; Reinout van Crevel; Stephen H Gillespie; Hans-Peter Grobbel; Barbara Kalsdorf; Irina Kontsevaya; Arjan van Laarhoven; Tomoki Nishiguchi; Anna Mandalakas; Matthias Merker; Stefan Niemann; Niklas Köhler; Jan Heyckendorf; Maja Reimann; Morten Ruhwald; Patricia Sanchez-Carballo; Dominik Schwudke; Franziska Waldow; Andrew R DiNardo Journal: Front Immunol Date: 2020-10-08 Impact factor: 7.561
Authors: Amy Oreskovic; Nuttada Panpradist; Diana Marangu; M William Ngwane; Zanele P Magcaba; Sindiswa Ngcobo; Zinhle Ngcobo; David J Horne; Douglas P K Wilson; Adrienne E Shapiro; Paul K Drain; Barry R Lutz Journal: J Clin Microbiol Date: 2021-07-19 Impact factor: 5.948
Authors: Amy Oreskovic; Adam Waalkes; Elizabeth A Holmes; Christopher A Rosenthal; Douglas P K Wilson; Adrienne E Shapiro; Paul K Drain; Barry R Lutz; Stephen J Salipante Journal: Int J Infect Dis Date: 2021-09-22 Impact factor: 3.623